I think that patient number 862 was for end of quarter. Probably an average closer to 800 I’d expect might be better in the calculation.
That would then be approximately $95,000/patient/quarter and translate to between 1000-1200 patients averaging across the period to hit guidance. Obviously lower in q2 and growing through the year.
- Forums
- ASX - By Stock
- Acadia
I think that patient number 862 was for end of quarter. Probably...
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.10 |
Change
-0.290(1.50%) |
Mkt cap ! $2.440B |
Open | High | Low | Value | Volume |
$19.55 | $19.65 | $18.88 | $3.265M | 170.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 5284 | $19.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.11 | 210 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 187 | 19.110 |
6 | 431 | 19.100 |
7 | 432 | 19.090 |
5 | 304 | 19.080 |
5 | 554 | 19.070 |
Price($) | Vol. | No. |
---|---|---|
19.120 | 33 | 4 |
19.130 | 241 | 11 |
19.140 | 243 | 4 |
19.150 | 363 | 5 |
19.160 | 281 | 3 |
Last trade - 11.57am 31/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
Previous Video
Next Video
SPONSORED BY The Market Online